Trabedersen, an antisense therapy capable of blocking protein translation of TGF‐β mRNA, showed encouraging preliminary results in patients with stage IV pancreatic cancer, malignant melanoma, colorectal cancer, and brain cancer [46, 47]. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.